Adult: For the treatment of reversible cases that may occur in association with bronchitis and emphysema. Dosage is individualised according to patient response. 20 mg 3-4 times daily. Child: 6-9 years or weighing <27 kg: 10 mg 3-4 times daily; >9 years or weighing ≥27 kg: Same as adult dose.
Oral Bronchial asthma
Adult: Dosage is individualised according to patient response. 20 mg 3-4 times daily. Child: 6-9 years or weighing <27 kg: 10 mg 3-4 times daily; >9 years or weighing ≥27 kg: Same as adult dose.
May be taken with or without food.
Pre-existing cardiac arrhythmias associated with tachycardia.
Patient with CV disease (e.g. ischaemic heart disease, hypertension, cardiac arrhythmias), hyperthyroidism, diabetes mellitus, glaucoma, hypokalaemia, or seizures. Not recommended for routine or long-term daily use for the management of acute asthma. Children. Pregnancy and lactation.
Significant: Immediate hypersensitivity reactions (e.g. urticaria, rash, bronchospasm, angioedema), changes in systolic and diastolic blood pressure. Cardiac disorders: Tachycardia, palpitations. Gastrointestinal disorders: Nausea, diarrhoea. Musculoskeletal and connective tissue disorders: Tremor. Nervous system disorders: Headache, nervousness, dizziness, insomnia, fatigue. Respiratory, thoracic and mediastinal disorders: Exacerbation of asthma.
Enhanced adverse effect with other sympathomimetic agents, MAOIs, and TCAs. Diminished bronchodilatory effect with non-selective β-blockers (e.g. propranolol).
Description: Orciprenaline is a bronchodilator which exerts its effect by stimulating the β-adrenergic receptors causing an increased conversion of ATP to 3'-5'-cyclic adenosine monophosphate(cAMP), resulting to bronchial smooth muscle relaxation.
Synonym: metaproterenol. Onset: Approx 30 minutes (bronchodilation). Duration: Approx 2-6 hours. Pharmacokinetics: Absorption: Well absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 1 hour. Bioavailability: Approx 40%. Metabolism: Undergoes extensive first-pass metabolism in the liver. Excretion: Via urine (as glucuronic acid conjugates).
R03CB03 - orciprenaline ; Belongs to the class of adrenergics for systemic use, non-selective beta-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases. R03AB03 - orciprenaline ; Belongs to the class of adrenergic inhalants, non-selective beta-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
Anon. Metaproterenol (Briggs Drugs in Pregnancy and Lactation). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 14/06/2021.Anon. Orciprenaline (Metaproterenol). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 14/06/2021.Buckingham R (ed). Orciprenaline sulfate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com . Accessed 14/06/2021.Metaproterenol Sulfate Syrup (Brant Ranch Prepack). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 17/06/2021.Metaproterenol Sulfate Syrup (Lannett Company, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 14/06/2021.Metaproterenol. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 17/06/2021.